



PCR-SSCP analysis in detecting point mutations targeting *rpoB*, *katG* and *inhA* genes for determining multi-drug resistance in *Mycobacterium bovis* and *Mycobacterium tuberculosis* strains

ALEX KIDANGAN¹ and RISHENDRA VERMA²

Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122 India

Received: 18 March 2014; Accepted: 18 July 2014

ABSTRACT

The usefulness of polymerase chain reaction-single stranded confirmation polymorphism (PCR-SSCP) for determination of rifampicin and isoniazid resistance in *Mycobacterium tuberculosis* and *M. bovis* cultures from human and animal origin was investigated. Mycobacteria (81) in the study included, viz. 12 MDR-TB samples, 35 sputum samples, 3 lung and lymphnode tissues from bovines and 11 *M. tuberculosis* and 18 *M. bovis* culture, *M. tuberculosis* H37Rv and *M. bovis* BCG strain). All the mycobacterial cultures were characterized on growth characteristics, biochemical test pattern, MTB complex specific IS6110 PCR and species specific 12.7 kb multiplex PCR. PCR-SSCP was used to determine resistance against rifampin by targeting *rpoB* gene (305 bp) and isoniazid by targeting *katG* (237 bp) and *inhA* (261 bp). Rifampicin resistance was detected by PCR-SSCP in 1 out of 12 MDR-TB samples (8.3%), while isoniazid resistance was detected in 66.7% of MDR-TB samples using PCR-SSCP of *katG* and 75% of MDR-TB samples using *inhA* SSCP analysis.

Key words: *Mycobacterium bovis*, *M. tuberculosis*, PCR-SSCP

Mycobacterium bovis and *Mycobacterium tuberculosis* cause bovine and human tuberculosis, respectively. The genetic similarities of these 2 species have made it difficult to differentially identify them in clinical samples. *M. tuberculosis* is responsible for over 95% of human tuberculosis cases. Emergence of multiple drug resistance (MDR) in tuberculosis impedes effective TB control across the globe. *M. bovis* appears to have a much wide host range than *M. tuberculosis* (Coleman and Cooke 2001) and the information about drug resistance in *M. bovis* has not been worked out as much as it is being reported in *M. tuberculosis*. The most common mechanisms of resistance to the primary anti-mycobacterial agents such as rifampin, isoniazid, and streptomycin in *M. tuberculosis* are mutations in the target genes, mostly point mutations, otherwise known as single nucleotide polymorphisms (SNPs). Several techniques use PCR-based strategies to rapidly detect mutations known to confer resistance. One such method is single strand conformation polymorphism (SSCP) analysis, which involves amplification by PCR of a segment of the gene encoding for the specific drug target and comparison of PCR products of drug-sensitive and drug-resistant strains by SSCP in which mutations usually result in an altered pattern. This study was undertaken to explore the utility of

PCR-SSCP in detecting point mutations targeting *rpoB*, *katG* and *inhA* gene for determining multi-drug resistance in *M. bovis* and *M. tuberculosis* strains.

MATERIALS AND METHODS

Mycobacteria samples: Samples (81) in the study included 12 MDR-TB cultures procured from the Tuberculosis Centre (NDTBC), New Delhi, 38 clinical samples, viz. 35 sputum samples collected from the District Tuberculosis Hospital, Bareilly, 3 lung and lymphnode tissue samples from bovines and 11 *M. tuberculosis* and 18 *M. bovis* culture, *M. tuberculosis* H37Rv and *M. bovis* BCG culture maintained at Mycobacteria Laboratory, Division of Bacteriology and Mycology, Indian Veterinary Research Institute (IVRI), Izatnagar. Thirty-five sputum samples were decontaminated by the modified method of Petroff (1915). The decontaminated deposit was inoculated onto the surface of a Lowenstein-Jensen (LJ) slant with 1% glycerol and 0.5% sodium pyruvate. 25 out of 35 sputum samples were positive for acid-fast bacilli under smear microscopy and 18 samples cultured on LJ medium yielded growth. The lungs and lymphnodes processed as per Marks (1972) also yielded growth on LJ medium.

DNA isolation and molecular confirmation: Genomic DNA was isolated directly from sputum samples. Briefly, sputum samples were mixed with 1.5–2 volumes of wash solution [6 M guanidinium hydrochloride, 50 mM Tris-Cl (pH 7.5), 25 mM EDTA, 0.5% Sarcosyl, 0.1 M β -

Present address: ²Joint Director (rishendra_verma@yahoo.com), Mycobacteria Laboratory, Division of Bacteriology and Mycology.

Table 1. Primer sequence used in MTB complex specific IS6110 region and species specific multiplex PCR targeting 12.7kb to differentiate *Mycobacterium tuberculosis* and *M. bovis*

Primer name	Sequence (5' to 3')	Primer length (bp)	Amplicon size (bp)
IS 6110 F	GACCACGACCGAAGAATCCGCTG	23	445
IS 6110 R	CGGACAGGCCGAGTTTGGTCATC	23	
12.7 kb F	CACCCGATGATCTTCTGTT	20	823 in <i>M bovis</i> 389 in <i>M tuberculosis</i>
12.7 kb R1	GCCAGTTTGCATTGCTATT	19	
12.7 kb R2	GACCCGCTGATCAAAGGTAT	20	

Table 2. Details of primers used for PCR-SSCP (Williams *et al.* 1994)

Primer name	Sequence (5' to 3')	Primer length (bp)	Amplicon size (bp)
<i>rpoB</i> F	CAGACGTTGATCAACATCCG	20	305bp
<i>rpoB</i> R	TACGGCGTTTCGATGAAC	18	
<i>katG</i> F	GCCCGAGCAACACCC	15	237bp
<i>katG</i> R	ATGTCCCGCGTCAGG	15	
<i>inhA</i> F	CGGGTGACCGAGGCGATCG	19	261bp
<i>inhA</i> R	GACCGTCATCCAGTTGTAG	19	

mercaptoethanol], incubated at room temperature for 20 min followed by addition of 15 ml sterile distilled water, centrifuged at 6,000×g for 20 min at room temperature. The supernatant was discarded carefully and the sediment was washed with 2 ml of wash solution and re-centrifuged as described above. The pellet was washed thoroughly with 10 ml water and after centrifugation the pellet was re-suspended in 500 µl 0.05% Tween-80 and used for smear microscopy (20 %), culture (40 %) and the remaining (40%) of the sample was gently layered on 2 volumes of 50% (w/v) sucrose solution and centrifuged at 12,000 × g for 5 min. The supernatant was discarded and the pellet was washed with distilled water and then re-suspended in 50 µL TE buffer containing 0.05% Tween 80 and incubated at 95°C for 10 min. The solution was cooled and centrifuged at 10,000 rpm for 5 min and the supernatant was stored at –20°C till further use (modified from Chakravorty and Tyagi 2005, Chakravorty *et al.* 2005, Victor *et al.* 1992, Thangaselvam *et al.* 2009).

Genomic DNA from mycobacterial culture was isolated by taking 2 loopful of the mycobacteria from the LJ slopes, suspended in 200 µL TE buffer (10mM Tris, 1mM EDTA pH 7.4) and incubated at 95°C for 10 min followed by centrifugation at 12,000 rpm for 5 min and supernatant was used as DNA template in subsequent PCR reaction. Lab maintained mycobacteria culture and mycobacterium culture from clinical samples were identified by MTB complex specific IS6110 region and species specific multiplex PCR targeting 12.7 kb region (Thangaselvam *et al.* 2009) (Table 1). DNA from 16 out of 25 acid-fast smear positive sputum and other mycobacteria showed 445 bp band in all samples indicating that they were *M. tuberculosis* complex and those yielded 389bp band in *M. tuberculosis* or 823 bp band as in *M. bovis*.

PCR-SSCP: PCR for *rpoB* (305bp), *katG* (237bp) and

inhA were carried out separately in 25µl volume containing 2.5 µl 10x PCR buffer, 200 µM dNTP mix, 5 pico mole forward and reverse primer each, 0.7 mM MgCl₂, 1 unit Taq DNA polymerase and 80–100 ng genomic DNA template. PCR cyclic condition for amplification of *rpoB*, *katG* and *inhA* gene were as follows: initial denaturation at 94°C for 10 min followed by 30 cycle each consisting of denaturation at 94°C for 1 min, annealing at 55°C for 1 min (*rpoB*, *katG*), 55°C for 1 min (*inhA*), extension at 72°C for 1 min final extension at 72°C for 10 min and holding at 4°C. The PCR amplicon (5µl) were electrophoresed along with 100 bp molecular weight marker on a 1.5% agarose gel in Tris borate EDTA (TBE) buffer at 70V for 30 min.

SSCP analysis: SSCP analysis of the amplified genes (Table 2) were carried out by electrophoresis of 5 µl PCR amplicon product in 12 and 15% polyacryamide gel at 150V at 4°C for 12 h followed by silver staining of gels for visualization of banding pattern (Bassam *et al.* 1991).

RESULTS AND DISCUSSION

Genes, *rpoB*, *katG* and *inhA* were amplified (Figs 1–3) in representative mycobacteria including 18 DNA isolated directly from sputum samples to explore the polymorphism (mutation) in these genes to detect multidrug resistance and subjected to SSCP analysis (Fig 1.1., 2.2., 3.3). DNA of all mycobacteria yielded similar patterns for *rpoB* genes by SSCP analysis. Only one MDR-TB DNA (3893) gave a slightly different pattern. This may be due to either mutation is not principal reason for conferring resistance or mutation occurred in *rpoB* gene exterior to 305bp region. In *E. coli* substitutions of amino acids 146 and 687, which is located exterior to the residues encoded by the 305-bp region characterized in the *M. tuberculosis* gene, have been reported to result in rifampin resistance (Ovchinnikov *et al.* 1983, Jin *et al.* 1988, Lisitsyn *et al.* 1984). Because of

the presumed large size of *rpoB* in *M. tuberculosis* (Honore *et al.* 1993) no attempt was made to characterize other regions. Our finding was supported by numerous reports such as 3 out of 121 RIFr strain (Kapur *et al.* 1994), 7% of the *M. tuberculosis* isolates with 100% resistance to rifampin (Williams *et al.* 1994), 2 out of 66 (3.3%) RIFr (Telenti *et al.* 1993) showed lack of mutation in *rpoB* targeted region, confirmed by DNA sequencing. For analyzing role of point mutation outside this 305bp region in evolving drug resistance TB organism, a 200bp fragment exterior to this genomic region was sequenced but mutations were not observed in that region in any strain. It clearly underlined that there may be another mechanism to acquire resistance in addition to point mutation.

In the present study, SSCP analysis of *katG* fragment (a 237 bp product) showed 2 patterns among the *M. tuberculosis* organisms differentiating INHr from INHs. Some of MDR *M. tuberculosis* strains (3915, 3916, 3917, 3139) showed a pattern similar to *M. tuberculosis* H37Rv indicating that mutation elsewhere may have been responsible for the resistance. Another finding was slightly different in electrophoretic mobility between *M. tuberculosis* and *M. bovis* which may be indicative of a possible nucleotide polymorphism between these 2 species, but which has no relevance with antibiotic resistance. None of the DNA samples tested had a complete deletion of *katG* deletion as reported by Zhang *et al.* (1992). Isoniazid resistance is associated with alterations in the catalase peroxidase gene (*katG*) or the *inhA* gene, which encodes an enzyme involved in mycolic acid bio-synthesis (Zhang *et al.* 1992, Banerjee *et al.* 1994). The *inhA* gene (261 bp) was analysed by SSCP. Two distinct patterns could be identified distinguishing antibiotic resistant and susceptible organisms. Sechi *et al.* (2000) studied molecular basis of isoniazid resistance in *M. bovis* strains isolated in Italy. To detect mutations involving isoniazid resistance of *M. bovis* they analysed *katG*, *oxyR-aphC* and *inhA* gene regions by sequencing. They failed to detect mutations for *oxyR-aphC*, but found polymorphisms in the *katG* and *inhA* gene regions. They found only one mutation in the *inhA* region however they found 3 mutations for the *katG* region, which may explain our finding of different banding patterns even among the MDR-TB samples.

Similar to *katG* gene, some MDR organisms showed common SSCP pattern resembling with SSCP pattern of drug susceptible mycobacterial isolates. Two out of 3 MDR isolates were showed same SSCP pattern with susceptible mycobacterial isolates that further strengthened hypothesis that resistance in MDR-TB may be due to either mutation in different gene or different region of same gene or mutations in different gene caused some physiological or metabolic changes that allowed mycobacteria organism in presence of commonly used first line of anti tuberculosis drug such as rifampin and isoniazid. In this study, 3 band SSCP pattern (*katG*) found in many isolates for this gene region may reflect the presence of 2 possible conformations for 1 of the DNA strands. This may be due to multiple

mutations in targeted region as reported 3 mutations in *katG* region and only 1 mutation in the *inhA* region (Sechi *et al.* 2001). A high concordance between SSCP and DNA sequencing for isoniazid resistance in Brazilian *M. tuberculosis* isolates was reported but 25% false results were interpreted on the basis of SSCP pattern (Silva *et al.* 2003). On the basis of our limited study in particular *M. bovis*, SSCP analysis seemed efficacious method for determining drug resistance, however, repeatability of the technique is less and resistance may be due to mutation in exterior to




Fig. 1. Amplification of 305 bp region of *rpo B* gene in *Mycobacterium* spp. M – 100 bp ladder; Lane-1 (*M. tuberculosis* H37RV); Lane-2 (*M. bovis* BCG); Lane-3 and 4 (MDR *M. tuberculosis*); Lane-5 and 6 (*M. tuberculosis*); Lane-7 (*M. bovis*); Lane-3 and 4 (MDR *M. tuberculosis*); Lane-5 and 6 (*M. tuberculosis*); Lane-7 (*M. bovis*)




Fig. 1.1 SSCP profile of *rpo B* gene. Lane-1 1 to 4 *M. bovis*; Lane 5 to 8 MDR-*M. tuberculosis*; Lane 9 to 12 *M. tuberculosis*; Lane 13 *M. tuberculosis* H37RV.





Fig. 2. Amplification of 237 bp region of *katG* B gene in *Mycobacterium* spp. M – 100 bp ladder; Lane-1 (*M. tuberculosis* H37RV); Lane-2 (*M. bovis* BCG); Lane-3 and 4 (MDR *M. tuberculosis*); Lane-5 and 6 (*M. tuberculosis*); Lane-7 (*M. bovis*).



BCG H37RV3/86 85/91128/92175/94 3892 3893 3915 3916 3917 3012

Fig. 2.1 SSCP profile of *katG* gene. Lane-1 1 *M. bovis* BCG; Lane 2 *M. tuberculosis* H37RV; Lane 3 and 4 *M. bovis*; Lane 5 and 6 *M. tuberculosis*; Lane 7 to 12. MDR-*M. tuberculosis*.

genomic region targeted, complex drug resistance mechanism, it should always be complemented by DNA sequencing and drug susceptibility testing to confirm drug resistance and understanding the mechanism of drug resistance.

ACKNOWLEDGEMENT

The authors thank Director, New Delhi Tuberculosis





Fig. 3. Amplification of 261 bp region of *inhA* B gene in *Mycobacterium* spp. Lane-1, and 1 and 6 MDR-*M. tuberculosis*; M – 100 bp ladder; Lane-1 (*M. tuberculosis* H37RV); Lane-2 (*M. bovis* BCG); Lane-3 and 4 (MDR *M. tuberculosis*); Lane-5 and 6 (*M. tuberculosis*); Lane-7 (*M. bovis*).



BCG H37RV44/097/09 8/09 534/7Sps22 38923893 3915 3916 3917 3012

Fig. 3.1 SSCP profile of *inhA* gene. Lane-1 1 and 6 MDR-*M. tuberculosis*; Lane 7 and 8. *M. tuberculosis*; Lane 9 to 11. *M. bovis*; Lane 12. *M. tuberculosis* H37RV; Lane 13. *M. bovis* BCG

Centre (NDTBC), Delhi Gate, New Delhi, for providing MDR *M. tuberculosis* strains.

REFERENCES

Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um K S, Wilson T, Collins D, de Lisle G and Jacobs Jr W R. 1994.

- inhA, a gene encoding a target for INH and ethionamide in *Mycobacterium tuberculosis*. *Science* **263**: 227–30.
- Bassam B J, Caetano-Anolles G and Gresshoff P M. 1991. Fast and sensitive silver staining of DNA in polyacrylamide gels. *Analytical Biochemistry* **196** (1): 80–83.
- Chakravorty S and Tyagi J S. 2005. Novel multipurpose methodology for detection of mycobacteria in pulmonary and extrapulmonary specimens by smear microscopy, culture, and PCR. *Journal of Clinical Microbiology* **43**: 2697–702.
- Chakravorty S, Dudeja M, Hanif M and Tyagi J S. 2005. Utility of USP smear microscopy, culture and PCR in the diagnosis of pulmonary tuberculosis. *Journal of Clinical Microbiology* **43**: 2703–08.
- Coleman JD and Cooke MM. 2001. *Mycobacterium bovis* infection in wildlife in New Zealand. *Tuberculosis* (Edinburgh) **81**:191–202.
- Honore N and Cole ST. 1993. Molecular basis of Rifampin resistance in *Mycobacterium leprae*. *Antimicrobial Agents Chemotherapy* **37**:414–18.
- Heym B, Honore N, Schurra C, Cole ST, Heym B, Truffot-Pernot C, Grosset JH, Banerjee A, Jacobs Jr WR and van Embden JDA. 1994. Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. *Lancet* **344**: 293–98.
- Miller LP, Crawford JT and Shinnick TM. 1994 The *rpoB* gene of *Mycobacterium tuberculosis*. *Antimicrobial Agents Chemotherapy* **38**: 805–11.
- Jin DJ and Gross CA. 1988 Mapping and sequencing of mutations in the *Escherichia coli rpoB* gene that lead to rifampicin resistance. *Journal of Molecular Biology* **202**: 45–48.
- Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN and Musser MJ. 1994. Characterization by automated DNA sequencing of mutations in the gene (*rpoB*) encoding the RNAPolymerase sub-unit in rifampin resistant *Mycobacterium tuberculosis* strains from New York city and Texas. *Journal of Clinical Microbiology* **32**: 1095–98.
- Lisitsyn NA, Sverdlov EV, Moiseyeva EP, Danilevskaya ON and Nikiforov VG. 1984. Mutation to rifampin resistance at the beginning of the RNA polymerase beta subunit gene in *Escherichia coli*. *Molecular and General Genetics* **196**:173–174.
- Ovchinnikov YA, Monastyrskaya GS, Guriev SO, Kalinina NF, Sverdlov ED, Gragerov AI, Bass IA, Kiver IF, Moiseyeva EP, Igumnov VN, Mindlin SZ, Nikiforov VG and Khesin RB. 1983. RNA polymerase rifampicin resistance mutations in *Escherichia coli*: sequence changes and dominance. *Molecular and General Genetics* **190**: 344–48.
- Marks J. 1972. Classification of the mycobacteria in relation to clinical significance. *Tubercle*, **53**: 259.
- Petroff SA. 1915. A new and rapid method for the isolation and cultivation of tubercle bacilli directly from the sputum and feces. *The Journal of Experimental Medicine* **21**: 38–42.
- Sechi LA, Sanguinetti M, Mollicotti PL Romano, Leori G, Delogu G, Boccia S, M La Sorda and Fadda G. 2001. Molecular basis of rifampin and isoniazid resistance in *Mycobacterium bovis* strains isolated in Sardinia Italy. *Antimicrob Agents Chemother.* **45**(6): 1645–48.
- Silva MSN, Senna SG, Ribeiro MO, Valim ARM, Telles MA, Kritski A, Morlock GP, Cooksey RC, Zaha A and Rossetti MLR. 2003. Mutations in *katG*, *inhA* and *ahpC* genes of Brazilian Isoniazid resistant isolates of *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* **41**(9): 4471–74.
- Telenti A, Imboden P, Marchesi F, Schmedheim T and Bodmer T. 1993. Direct automated detection of rifampin-resistant *Mycobacterium tuberculosis* by polymerase chain reaction and single stranded conformation polymorphism analysis. *Antimicrobial Agents Chemotherapy* **37**: 2054–58.
- Thangaselvam M, Kidangan A, Verma Rishendra and Ramane SP. 2009. Molecular Detection and Differentiation of *Mycobacterium tuberculosis* Complex in Human Sputum Samples Using PCR Assays: A Preliminary Report. *Indian Journal of Veterinary Research* **18**(2):50–54.
- Victor T, Du Toit R and van Helden PD. 1992. Purification of sputum samples through Sucrose improves detection of *Mycobacterium tuberculosis* by Polymerase Chain Reaction. *Journal of Clinical Microbiology* **30**(6): 1514–17.
- Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, Nolan CM, Abe C, Sticht-Groh V and Gillis TP. 1994. Characterization of Rifampin resistance in pathogenic *Mycobacteria*. *Antimicrobial agents and Chemotherapy* **38**(10): 2380–86.
- Zhang Y, Heym B, Young D and Cole S. 1992. The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*. *Nature* **358**: 591–93.